Quick Summary Q2 adjusted EPS reached $7.45, surpassing the Street estimate of $6.21 by $1.24 Quarterly revenue totaled $49.8 billion, exceeding the $48.63 billion projection Operating margin
Elevance Health delivered a substantial beat on second-quarter earnings Wednesday, yet shares tumbled as market participants focused intensely on deteriorating profit margins.
Shares of ELV plunged more than 9% during premarket activity following the quarterly report. Prior to earnings, the stock had climbed nearly 22% year-to-date in 2026, finishing Monday’s session at $426.79.
The company delivered adjusted earnings of $7.45 per share, sailing past Wall Street’s consensus projection of $6.21 by a substantial $1.24 margin. Total revenue hit $49.8 billion, representing a modest 0.8% year-over-year increase and topping the anticipated $48.63 billion.
ELEVANCE HEALTH $ELV Q2’26 EARNINGS HIGHLIGHTS
Revenue: $49.8B (Est. $48.6B)
; +0.8% YoY
; +80 bps YoY
Raises FY26 Guide:
— Wall St Engine (@wallstengine) July 15, 2026
Despite the impressive earnings performance, investors weren’t convinced. The company’s operating margin contracted sharply to 3.5% compared to 4.9% recorded in the corresponding quarter last year. Similarly, the adjusted operating margin deteriorated from 5.0% to 3.6%.
Within the flagship Health Benefits division, the margin story proved even more concerning. That segment’s operating margin compressed to 2.1% from 3.8% a year earlier.
The benefit expense ratio climbed 80 basis points on a year-over-year basis to 89.7%. Rising medical costs within government-sponsored programs fueled this expansion, though stronger performance in Individual ACA marketplace plans provided partial relief.
Elevance enhanced its full-year adjusted EPS forecast to a minimum of $27.00, representing an increase from the prior floor of at least $26.75. The new guidance slightly exceeds the analyst consensus estimate of $26.91. The company also elevated its operating cash flow projection to at least $6.0 billion.
This represents the second upward revision in recent months. Management initially raised guidance in April before reaffirming the improved outlook in June.
CEO Gail Boudreaux noted that results “exceeded our outlook, supported by disciplined execution and improved operating performance across our diversified portfolio.”
Total medical membership reached approximately 44.9 million as of the end of June 2026, declining by 469,000 members from the previous quarter. The drop stemmed from a commercial fee-based client transition combined with anticipated membership losses in Individual ACA and Medicaid programs.
The Health Benefits division generated $42.7 billion in quarterly revenue, marking a 3% year-over-year uptick. Meanwhile, Carelon revenue expanded 6% to reach $19.2 billion.
Wall Street analysts had entered the earnings event with generally positive sentiment. TD Cowen analyst Ryan Langston upgraded his Elevance price objective from $400 to $465 on Tuesday. Cantor Fitzgerald similarly increased its target from $400 to $450.
Medicaid profitability continues demanding close attention. CFO Mark Kaye stated during a Goldman Sachs healthcare conference in June that expenses in this segment remained elevated, with management targeting a full-year margin around -1.75%.
UBS analyst A.J. Rice characterized that margin target as “conservative,” implying potential upside opportunity.
Elevance’s earnings arrived one day ahead of UnitedHealth Group, the industry’s dominant force, which is scheduled to release quarterly results Thursday.
The post Elevance Health (ELV) Stock Plunges 9% Despite Crushing Earnings — The Margin Problem Explained appeared first on Blockonomi.
